Cronos Group (CRON) Projected to Post Quarterly Earnings on Thursday

Cronos Group (NASDAQ:CRON) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cronos Group to post earnings of $0.01 per share and revenue of $38.5060 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Cronos Group Trading Up 0.8%

Shares of CRON stock opened at $2.67 on Thursday. The firm’s 50 day moving average is $2.70 and its 200 day moving average is $2.58. The stock has a market capitalization of $1.02 billion, a P/E ratio of 26.70 and a beta of 0.80. Cronos Group has a 12 month low of $1.60 and a 12 month high of $3.43.

Institutional Investors Weigh In On Cronos Group

A number of institutional investors and hedge funds have recently bought and sold shares of CRON. Brooklyn Investment Group grew its stake in Cronos Group by 5,733.0% in the 3rd quarter. Brooklyn Investment Group now owns 10,966 shares of the company’s stock worth $30,000 after buying an additional 10,778 shares in the last quarter. Scientech Research LLC purchased a new position in Cronos Group in the third quarter worth $32,000. HighTower Advisors LLC increased its stake in Cronos Group by 323.4% in the fourth quarter. HighTower Advisors LLC now owns 12,959 shares of the company’s stock valued at $34,000 after acquiring an additional 18,761 shares during the last quarter. Sender Co & Partners Inc. bought a new position in Cronos Group in the third quarter valued at $35,000. Finally, Envestnet Asset Management Inc. purchased a new stake in Cronos Group during the second quarter valued at about $36,000. 8.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CRON shares. Canaccord Genuity Group began coverage on Cronos Group in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Cronos Group in a report on Monday, December 29th. Wall Street Zen upgraded Cronos Group from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $2.30 target price on shares of Cronos Group in a report on Wednesday, January 14th. Finally, Zacks Research downgraded shares of Cronos Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $2.30.

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.